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Abstract
Objectives: The objective of this study was to prove con-
cepts in the characterization of suicidal patients and the pos-
sible usefulness of those markers to potentially identify pa-
tients with a higher risk for suicidality. Methods: Patients 
with a recent suicide attempt were compared with patients 
suffering from depression, adjustment disorder, anxiety, or 
eating disorders without suicidality, healthy controls and re-
mitted patients with a history of at least 1 suicide attempt 
(≥1 year). We analyzed impulsivity (Barratt Impulsivity Scale, 
BIS) and saliva cortisol concentrations. Results: Indepen-
dently of suicidality and disease state patients display higher 
BIS scores than healthy controls. Saliva cortisol levels tend to 
be higher in patients in the acute disease state than in remit-
ted patients and healthy controls. Conclusions: Saliva corti-
sol may be a useful marker that reveals alterations in nonsui-
cidal patients suffering from depression, adjustment disor-
der, anxiety, or eating disorders who might be at risk.
© 2018 S. Karger AG, Basel
Introduction
About a million people die by suicide every year. This 
is a “global” mortality rate of 16 per 100,000, or 1 death 
every 40 s [1]. The suicide rate has appeared to be re-
markably stable at this high level worldwide since 1950 
[2]; thus, suicide and nonfatal suicidal behavior remain 
significant public health issues. Prevention is an impor-
tant strategy to limit the burden of this behavior, and the 
identification of potential risk factors (state and trait 
markers) is essential. Although suicidality is an individ-
ual problem caused by multiple factors, different person-
ality traits and biological state markers are known to play 
a critical role in most suicidal patients. The tendency to 
impulsive behavior is an acknowledged and usually in-
herent risk factor for later suicidal behavior [3–10]. Cor-
tisol, a highly relevant hormone for adapting to stressful 
life events, was also found to correlate with suicidality 
[11–15]. Płocka-Lewandowska et al. [16] investigated 
cortisol levels in schizophrenic patients at 2 different 
time points. They have shown that cortisol levels were 
significantly higher in patients with previous suicide at-
D
ow
nl
oa
de
d 
by
: 
S
LU
B
 D
re
sd
en
   
   
   
   
   
   
 
19
4.
95
.1
43
.1
36
 -
 4
/1
6/
20
20
 8
:4
9:
47
 A
M
Lewitzka/Bauer/Ripke/Bronisch/GüntherNeuropsychobiology2
DOI: 10.1159/000484664
tempts, and baseline cortisol was higher in the patients 
who were to make a future attempt [16]. Researchers 
have reported lower cortisol levels in suicidal patients 
compared to controls [17], but a hyperactive hypotha-
lamic-pituitary-adrenal (HPA) axis was generally associ-
ated with suicidality [18–21]. Van Heeringen et al. [22] 
revealed that elevated urine cortisol levels correlate sig-
nificantly with a personality profile characterized by in-
creased novelty seeking and impulsivity in violent sui-
cidal behavior. 
The aims of the present study were to analyze the 
trait-like personality characteristic impulsivity, and to 
measure the state-dependent biological marker saliva 
cortisol. Our analyses were done in patients with a re-
cent suicide attempt compared to healthy controls, pa-
tients suffering from depression, adjustment disorder, 
anxiety or eating disorders without suicidality, and pa-
tients with a longer history of suicide attempt. The group 
of patients suffering from depression, adjustment disor-
der, anxiety, or eating disorders is named as psychiatric 
patients within the following paragraphs. Characteriza-
tion of each group could help to delineate patients with 
a higher risk for suicidality. We assumed that patients 
with a recent suicide attempt would exhibit higher levels 
of impulsivity as well as changes in their diurnal cortisol 
secretion pattern than healthy controls. We were espe-
cially interested in detecting any differences between 
suicide attempters and nonsuicidal controls. This might 
hint at factors probably differentiating the 2 groups, 
with relevance for preventive strategies in the clinical 
context. 
Material and Methods
Participants and Recruitment 
Data from 2 separate studies were summarized for the pur-
pose of this publication. The first study (No. 1) was carried out 
in conjunction with a local project (Dresden, Germany) investi-
gating impulsivity, cognitive performance, and cortisol levels in 
suicide attempters. The second study (No. 2) was conducted 
within the “German Network on Depression and Suicidality,” 
which included the investigation of several neurobiological pa-
rameters and psychometric tests (for an overview, see Bronisch 
et al. [23]). Both studies were conducted in parallel at the same 
time and with identical means of assessing impulsivity and cor-
tisol measurement. Both studies were approved by our local eth-
ics committees. Patients were enrolled after having been admit-
ted to the inpatient ward or after having been referred to the 
outpatient department. Healthy controls were recruited after re-
sponding to a call for study participation in a local bulletin. All 
patients and healthy controls gave their written consent to par-
ticipate in the study. All patients and healthy controls were Cau-
casians of European descent. Diagnoses were based on the MINI 
(Mini-International Neuropsychiatric Interview) and ICD-10. 
All diagnostic and treatment information was reviewed by a pan-
el of experienced psychiatrists. For inclusion and exclusion crite-
ria, see Table 1.
Finally, these 2 studies led to 4 different but age- and gender-
matched groups (later called groups 1, 2, 3, and 4), which were 
included in the present study’s analyses. For a detailed overview of 
these 4 groups, please see Table 2.
Assessment of Impulsivity 
The focus of this study was the self-reported impulsivity mea-
sured in all groups via the Barratt Impulsivity Scale (BIS [24, 25]), 
a questionnaire to assess general impulsiveness. It consists of 30 
items that consider the multifactorial nature of this behavior. The 
items are grouped in 6 first-order factors (attention, motor impul-
siveness, self-control, cognitive complexity, perseverance, cogni-
tive instability) and 3 second-order factors (attentional impulsive-
ness, motor impulsiveness, and nonplanning impulsiveness). Each 
item is scored on a 4-point scale (1: rarely/never; 2: occasionally; 
Table 1. In- and exclusion criteria
Study No. 1 Study No. 2
Inclusion criteria Suicide attempt ≥1 year ago Suicide attempt within the last 3 weeks
Patients of both genders Patients of both genders
Age: 18–50 years Age: 18–75 years
Patients with affective disorders (major depression, dysthymia,  
adjustment disorder)
Drug-free for a minimum of 2 weeks prior to inclusion (5 weeks for 
fluoxetine and lithium)
Exclusion criteria Organic brain diseases Organic brain disease
Schizophrenia or schizoaffective disorder Schizophrenia or schizoaffective disorder
Acute or chronic somatic conditions Acute or chronic somatic conditions
Currently depressive episode Pregnant or lactating
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3: often; 4: almost always/always). The total score can be calculated 
using the different factors. In general, the higher the overall score, 
the more impulsive someone is. 
Cortisol Sampling
Saliva was collected with a Salivette® (Sarstedt, Nürnbrecht, 
Germany), and cortisol levels were determined using a commercial 
ELISA kit (IBL, Hamburg, Germany). All participants were in-
structed to insalivate a cotton roll for at least 2 min and to refrain 
from drinking, eating, smoking, or brushing teeth at least 60 min 
before sampling. The cotton roll was placed into a sterile plastic 
insert in a vial and stored at –20  ° C until assessments. Saliva was 
collected as follows: patients from group 1 (suicide attempt ≥1 
year) and 2 (healthy controls) were requested to collect saliva in 
the morning between 8: 00 and 9: 00 a.m. Group 3 (suicide attempt 
<3 weeks) and group 4 (psychiatric controls) had 2 collection 
times: in the morning around 8 a.m. and in the evening at 7 p.m. 
Sampling the morning saliva took place at least 1 h after awaking. 
We did this to circumvent the cortisol-awakening response that 
takes place during the first 30–45 min after morning awakening 
[26]. Saliva sampling was not possible in some cases due to an acute 
psychiatric crisis or xerostomia. In other cases the collected saliva 
was insufficient for ELISA analysis.
Statistical Procedures
SPSS 23.0 for Windows (SPSS GmbH Software, Munich, Ger-
many) was used for statistical analyses. ANOVAs were calculated, 
and in case of significance (p < 0.05) and whenever appropriate 
(homogeneity of variance is given), post hoc tests (Bonferroni) 
were applied. If the homogeneity of variance was not ensured, we 
carried out another post hoc test (Tamhane T2). The size of the 
samples available for data analysis varied. 
Table 2. Group assignment, age, and diagnoses
Study No. 1 Study No. 2
group 1: group 2: group 3: group 4:
SA >1 year (1.4±0.8) healthy controls SA within the last 3 
weeks (13.3 ± 8.5 days)
psychiatric controls 
(without SA)
Source of subjects Impulsivity study Impulsivity study Neurobiology study Neurobiology study
Outpatient department 
Dresden (Germany)
Local volunteers 
Dresden (Germany)
Different German 
study centers
Different German study 
centers
Patients, n 37 42 63 22
Sex 17 males
20 females
19 males
23 females
31 males
32 females
11 males
11 females
Mean age, years
Males
Females
36.47±7.15
35.84±9.00
36.44±8.01
37.87±8.50
39.51±15.59
36.84±13.98
41.45±12.94
33.90±9.51
Medication Medication allowed 
No medication: n = 11
SSRI ± BZ: n = 11
Tricyclic AD ± BZ: n = 4
Neuroleptics ± AD: n = 9
BZ: n =2
No medication Drug-free for a  
minimum of 2 weeks 
prior to study inclusion 
(fluoxetine and lithium: 
5 weeks) 
Drug-free for a  
minimum of 2 weeks 
prior to study inclusion 
(fluoxetine and lithium: 
5 weeks)
Diagnoses1, n
Major depression 14 (7 male, 7 female) No diagnoses 35 (15 male, 20 female) 12 (5 male, 7 female)
Dysthymia 0 2 (1 male, 1 female) 3 (3 male, 0 female)
Adjustment disorder 0 14 (8 male, 6 female) 4 (2 male, 2 female)
Agoraphobia 0 1 (0 male, 1 female) 0
Eating disorder 6 (0 male, 6 female) 0 0
PTSD 0 1 (0 male, 1 female) 0
Alcohol abuse 18 (8 male, 9 female) 0 0
Social phobia 0 2 (2 male, 0 female) 0
GAD 24 (7 male, 17 female) 0 1 (0 male, 1 female)
Results are expressed as numbers or as means ± SD. The table shows the main characteristics of each study group; SA, suicide attempt; 
SSRI, selective serotonin reuptake inhibitor; BZ, benzodiazepine; AD, antidepressant; PTSD, posttraumatic stress disorder; GAD, general 
anxiety disorder. 1 Multiple diagnoses were allowed for each patient in groups 1, 3, and 4.
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Results
Impulsivity
We observed no significant gender differences in the 
overall BIS scores (♂ 67.86 ± 1.48; ♀ = 67.12 ± 1.24; 
F(1, 126) = 0.15; p = 0.70). The BIS score differed signifi-
cantly among all 4 groups (F(3, 126) = 12.52; p = 0.00) 
independently of the patients’ gender (F(3, 126) = 1.13, 
p = 0.338). Healthy controls (group 2) displayed the low-
est BIS scores (59.86 ± 1.59) of all groups. The healthy 
controls’ BIS score was significantly lower than that of the 
psychiatric patients (69.57 ± 2.50, p = 0.006), those with 
a recent suicide attempt (73.73 ± 1.66), or with one more 
than a year ago (66.79 ± 1.69, p = 0.013). Patients with a 
recent suicide attempt (<3 weeks) tended to display the 
highest BIS scores (73.73 ± 1.66), a factor also significant-
ly different compared to patients whose history of suicide 
attempts was more than a year ago (p = 0.033). Figure 1 
presents impulsivity within the 4 groups (means ± SEM).
Morning Cortisol Concentration
As presented in Figure 2 (means ± SEM) patients 
acutely suffering from a psychiatric disease (23.33 ± 6.53 
ng/mL) or a recently attempted suicide (17.97 ± 3.46 ng/
mL) have significantly different morning cortisol levels 
(F(3, 118) = 2.85, p = 0.041) than healthy controls (8.16 ± 
3.43 ng/mL) and patients who had attempted suicide 
more than a year ago (7.81 ± 3.62 ng/mL). We were un-
able to statistically confirm these differences at the group 
level via pairwise comparisons due to the inhomogeneity 
of variance, especially in the females’ data. 
In general, females (19.77 ± 3.17 ng/mL) also differed 
significantly (F(1, 118) = 5.98, p = 0.016) from males 
(8.87 ± 3.13 ng/mL), an effect that interacts slightly 
with the group affiliation (F(3, 118) = 2.54; p = 0.06). 
Diurnal Cortisol Rhythm
As shown in Figure 3 (means ± SEM) only complete 
data were included in our data analysis (that is, morning 
and evening cortisol levels available per patient). The 
time of the day significantly influenced (F(1, 100) = 4.80; 
p = 0.031) the cortisol levels in patients who had attempt-
ed suicide (group 3). Morning cortisol levels (13.80 ± 4.14 
Group 1
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Fig. 1. Overall BIS scores (mean ± SEM) to assess impulsivity in 
groups 1–4. SA, suicide attempt.
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Fig. 2. Cortisol in morning saliva (mean ± SEM) in groups 1–4. SA, 
suicide attempt.
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Fig. 3. Cortisol in saliva comparing groups 3 and 4. SA, suicide at-
tempt.
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ng/mL) were significantly higher than the evening levels 
(4.05 ± 1.62 ng/mL). In patients acutely suffering from a 
psychiatric disease, morning (12.5 ± 7.39) and evening 
levels (12.36 ± 6.31) did not differ (F(1, 36) = 0.000; p = 
0.988). 
Discussion
Personality traits tend to be inherent, and they make 
attractive targets for suicidality research and the develop-
ment of prevention strategies (for an overview, see Brezo 
et al. [27]). Impulsivity is a target known to be involved 
in suicidality. Psychiatric patients exhibit generally great-
er impulsivity than controls [28, 29], and impulsivity is 
considered as a trait that characterizes individuals at high 
risk for suicide attempts regardless of the psychiatric di-
agnosis [30]. 
We detected the lowest overall impulsivity levels in our 
healthy controls. All our patients, independently of acute 
illness, remission phase, with or without acute suicidality, 
displayed significantly higher overall impulsivity (BIS 
score). This fact associates impulsivity with psychiatric 
illness independently of the acute disease state and there-
fore reinforces high impulsivity as personal characteristic 
(trait marker) in psychiatric patients [28, 29]. We identi-
fied the highest impulsivity in patients who had attempt-
ed suicide (in most cases, several days before study inclu-
sion); a significant difference from the psychiatric pa-
tients in remission and from those whose suicide attempt 
had taken place at least a year ago. We conclude that be-
sides generally higher impulsivity in psychiatric patients, 
there must be other internal or environmental factors that 
enhance self-rated impulsivity and are associated with an 
acute suicidal act. Impulsivity is therefore a key personal-
ity trait for diagnostic purposes, as well as a probable tar-
get for psychotherapy in the prevention of further suicide 
attempts. 
Although very useful, appraising complex personality 
traits such as self-rated impulsivity is a complex and de-
manding endeavor requiring personal resources and 
time. Moreover, it cannot be generally applied to every 
patient. Markers that are obtainable rapidly and easily are 
also needed. Measuring cortisol in saliva is just such a 
comparatively easy method. Cortisol is a steroid hormone 
whose saliva concentration reflects precisely the concen-
tration of free cortisol in plasma [31–34]. Its production 
in the adrenal cortex and its diurnal secretion are rhyth-
mic and controlled by the pituitary gland. Morning levels 
tend to be higher than evening levels [35]. Cortisol secre-
tion peaks within the first 45 min after awakening and 
then fall slightly during the day [26]. We found marked 
group differences in morning plateau cortisol levels. We 
observed a general trend toward higher cortisol levels in 
acute psychiatric patients regardless of whether they were 
suicidal or not, although the variance was high and main-
ly caused by the patient’s sex. The females in particular 
displayed higher cortisol levels than the men in these 2 
groups (3 and 4). There is evidence that cortisol concen-
trations are influenced by the menstrual cycle and that 
cortisol responsiveness following a psychosocial stressor 
is significantly higher during the follicular phase [36]. 
Since we had not considered the menstrual cycle, we can 
only speculate that that phase might also have influenced 
the cortisol level in the female patients in acute stress 
from their disease and previous suicide attempt. In gen-
eral, stress per se is a crucial generating factor in major 
depression [37], and most of the patients we analyzed suf-
fer from acute major depression. Thus, the higher cortisol 
levels we observed are perhaps more likely associated 
with an altered stress-regulating system, i.e., the HPA 
axis, with concomitant higher basal cortisol levels or 
greater stress sensitivity. It is also discussed that different 
types of depression have different effects on the HPA sys-
tem. A study by Lamers et al. [38] investigated whether 
biological parameters such as cortisol may be influenced 
by the subtype of depression. They found a lower cortisol 
and lower diurnal cortisol slope in atypical depression 
compared with melancholic depression. They indicated 
that atypical depression is a distinct phenomenon. 
Medication prior to study inclusion was very limited; 
in particular, selective serotonin reuptake inhibitors that 
indirectly regulate the HPA axis [39] were not allowed. 
We can effectively rule out the possibility that the differ-
ent cortisol levels in psychiatric patients with or without 
suicidality compared to healthy controls and remitted pa-
tients were influenced by medication.
We also analyzed the cortisol day profile in acute psy-
chiatric patients with or without a suicide attempt to 
more specifically characterize these groups and elucidate 
a marker that might differentiate these two groups. We 
detected a consistent cortisol profile, that is, high morn-
ing cortisol levels and low ones in the evening, in acute 
psychiatric patients who had attempted suicide within the 
3 weeks before study inclusion. In contrast, cortisol levels 
were diminished in the acute psychiatric patients. We as-
sume that patients with a suicide attempt within 3 weeks 
prior to the cortisol measurement were still in acute stress, 
and some of them may still be at risk to attempt suicide. 
The sensitivity of the HPA stress response system may be 
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particularly compromised in individuals who have made 
a recent suicide attempt. This was also shown in a study 
by O’Connor et al. [40] who investigated 3 different 
groups: individuals who had previously made a suicide 
attempt, individuals who had thought about suicide (sui-
cide ideators), and control participants. They measured 
cortisol levels throughout participants who completed 
the Maastricht Acute Stress Test. Participants who had 
made a previous suicide attempt exhibited significantly 
lower aggregate cortisol levels during the Maastricht 
Acute Stress Test compared to participants in the control 
group; suicide ideators were intermediate to both groups. 
Limitations 
The present study has methodological strengths and 
shortcomings. Investigations in the field of suicidality are 
rare, and the availability of patient data shortly after a sui-
cide attempt is the exception rather than the rule. It is the 
strength of this study that we had access to a nearly homo-
geneous pool of patients regarding their main diagnoses 
(major depression). On the other hand, one group consist-
ed of patients with other diagnoses such as alcohol abuse or 
eating disorders; thus, we could not exclude influences on 
the HPA system and therefore limits of our findings. 
Medications were extremely limited, thus, our results 
were not skewed. The percentages of males and females 
were nearly equal; however, the menstrual phase in wom-
en should be incorporated in future studies. We were able 
to recruit a sufficient number of study subjects; however, 
the patients’ data were not always complete for different 
reasons. 
The absence of a cortisol profile for all 4 groups is an-
other limitation. Groups 1 and 2 had only a cortisol mea-
surement in the morning whereas groups 3 and 4 had 2 
sampling times. 
Saliva sampling was not always possible (or the at-
tempt failed) because of xerostomia, for instance. Cortisol 
levels are also affected by smoking [41–43]. We did not 
take smoking habits into account in this study, but it 
should be in future studies. Finally, whether suicidality, 
impulsivity, depression, and others are useful tools to 
classify patients in neurobiological research remains to be 
proven.
Conclusion
In summary, psychiatric patients are characterized by 
high impulsivity, especially those who had attempted sui-
cide shortly before study inclusion. Saliva cortisol con-
centrations tend to be higher only in those psychiatric 
patients acutely suffering from affective disorders (de-
pression and adjustment). The diurnal cortisol profile is 
striking in patients who are acutely ill but without suicid-
ality. Our data lead us to suggest that high impulsivity is 
a characteristic personality trait marker in psychiatric pa-
tients even after remission. Saliva cortisol levels are easy 
to obtain and suitable to differentiate patients in an acute 
psychiatric crisis. Further investigation is needed to re-
veal those patients within this patient group who are at 
particular risk for a suicide attempt, and we recommend 
analysis of the diurnal saliva cortisol profile as a worth-
while parameter.
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